Incyte (INCY) Tops Q2 EPS by 45c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 2, 2022 7:00 AM EDTTotal revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664 million (+15% Y/Y) Jakafi® (ruxolitinib) net product revenues of $598 million in Q222 (+13% Y/Y) driven by volume growth; raising the bottom end of full year guidance to new range of $2.36 to $2.40 billion Opzelura (ruxolitinib) cream approved as first and only treatment for repigmentation of nonsegmental vitiligo in patients aged 12 and older; launch progressing in atopic dermatitis (AD) Multiple approvals including Olumiant® (baricitinib) as the first and only systemic treatment approved for alopecia areata in the... More
